|
May 18th is HIV Vaccine Awareness Day
|
The Alliance Coordinating Office would like to thank all the many communities, health care professionals, scientists and all those who are working towards the discovery of a safe and effective HIV vaccine.
In commemoration of HVAD 2016 we’re highlighting the voices of those who shared their thoughts on the need for an HIV vaccine.
VIEW GALLERY
|
|
HIV Env Vaccine Manufacturing Workshop
September 15, 2016 – NIAID, 5601 Fishers Lane, Rockville, MD, USA
Global HIV Vaccine Enterprise
Following up on the successful 2015 Env Manufacturing workshop organized by the National Institutes of Health, the Global HIV Vaccine Enterprise will be hosting a workshop to review progress in HIV Env vaccine manufacturing. The workshop will focus in depth on a set of key challenges, review latest developments in the field, and cover relevant lessons learned from other fields. For more information, contact yvoronin@vaccineenterprise.org.
|
|
2nd International Workshop on Microbiome in HIV, Pathogenesis, Prevention and Treatment
November 17 & 18, 2016 – Bethesda, MD, USA
Virology Education
The understanding of the human microbiome continues to grow rapidly; however information on the role of HIV infection on changes in the microbiome is still limited. Whereas research in this area may be presented at major conferences, there is often limited time for in-depth discussion and debate among cross-disciplinary experts on new data and their implications. The aim of this workshop is to provide increased opportunities for discussion and exchange of knowledge following formal presentation of the latest research.
MORE INFORMATION
|
|
Vitamin A or E and a catechin synergize as vaccine adjuvant to enhance immune responses in mice by induction of early IL-15 but not IL-1ß responses.
Immunology. 2016 May 2. doi: 10.1111/imm. 12614. [Epub ahead of print]
Patel S, Akalkotkar A, Bivona JJ 3rd, Lee JY, et al.
Vitamins A and E and select flavonoids in the family of catechins are well-defined small molecules that if proven to possess immunomodulatory properties, hold promise as vaccine adjuvants and various therapies. These data show that this approach in nutritive vaccine adjuvant design holds promise for the development of potentially safer effective vaccines.
READ MORE
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.
Nature. 2016 May 5;533(7601):105-9.doi:10.1038/nature17677.Epub 2016 Apr 27.
Gautam R, Nishimura Y, Pegu A, Nason MC, et al.
Despite the success of potent anti-retroviral drugs in controlling human immunodeficiency virus type 1 (HIV-1) infection, little progress has been made in generating an effective HIV-1 vaccine. Although passive transfer of anti-HIV-1 broadly neutralizing antibodies can protect mice or macaques against a single high-dose challenge with HIV or simian/human (SIV/HIV) chimaeric viruses (SHIVs) respectively, the long term efficacy of a passive antibody transfer approach for HIV-1 has not been examined.
READ MORE
For more research articles, the ACO sends a weekly curated digest to all Alliance Virtual Community members. Register for the Alliance Virtual Community or learn more.
|
|
Funding Opportunities
National Institutes of Health (NIH): Human Tissue Models for Infectious Diseases
LOI SUBMISSION DEADLINE: June 6, 2016
APPLICATION DEADLINE: July 6, 2016 by 5:00 PM local time of applicant organization
The purpose of this FOA is to establish multidisciplinary research Centers that focus on the development of novel, in vitro human tissue model systems that can advance understanding of infectious diseases through overcoming longstanding obstacles that inhibit basic and translational research. Each Center will include investigators with appropriate expertise in infectious diseases, human tissue engineering, and the human microbiome, where relevant, to develop innovative models that recapitulate pathophysiology and host response, and provide relevant predictive outcomes for human diseases.
MORE INFORMATION
National Institutes of Health (NIH): Advancing HIV Therapeutic Vaccine Science
LOI DEADLINE: June 28, 2016
APPLICATION DEADLINE: July 28, 2016 by 5:00 PM local time of applicant organization
This Funding Opportunity Announcement (FOA) solicits applications that will advance understanding of vaccine regimens and immune responses that sustainably suppress viral loads in HIV-infected individuals. Applications should propose small, multi-arm, comparative clinical trials designed to identify correlations between levels of induced immune response and HIV virologic control. Vaccines may be combined with adjuvants and/or other modifiers of the immune response to HIV.
MORE INFORMATION
More Funding Resources
|
|
|
| |
You are receiving this email because you registered to receive news updates from the ACO
or you are a member of a
CHVI-funded
project team.
|
|
Annual Update
|
|
|
The Annual Report offers highlights of ACO activities over the past fiscal year.
Read our 2014-2015 Annual Update.
|
White Paper
|
The ACO has developed a White Paper to foster effective coordination of key players across the Canadian HIV vaccine research landscape.
|
|
|
About Us
|
|
The ACO was established by the Government of Canada and the Bill & Melinda Gates Foundation in November 2011 at the International Centre for Infectious Diseases (ICID), a
not-for-profit,
non-governmental organization based in Winnipeg.
|
|
|
Address
|
|
ACO at
International Centre for Infectious Diseases
515 Portage Avenue
Winnipeg, MB, Canada
R3B 2E9
Tel.: 204 946 0908
Fax: 204 946 0927
email:
aco@icid.com
|
|
| |
|
Follow Us:
|
|
|
| |
| |
| |
| |
| |
|
